Scoping Review on Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers
Abstract
<h2>Cover Page</h2> <p>Scoping Review on Pharmacological Agents for Preventing Decompensation in Compensated Liver Cirrhosis Excluding Beta-Blockers</p> <p>Student Name</p> <p>Course Name</p> <p>Instructor Name</p> <p>Institution</p> <p>Date</p> <h2>Study Selection and Evidence Identification Process</h2> <h3>PRISMA Flow Diagram</h3> <h3>Study Selection Results</h3> <h2>Characteristics of Included Pharmacological Studies</h2> <h3>Overview of Included Studies</h3> <h3>Therapeutic Classes Evaluated</h3> <h3>Study Designs and Patient Populations</h3> <h3>Clinical Outcomes Across Included Studies</h3> <h2>Comparative Clinical Outcomes of Pharmacological Interventions</h2> <h3>Statins</h3> <h3>Rifaximin</h3> <h3>Anticoagulants</h3> <h3>SGLT-2 Inhibitors</h3> <h3>GLP-1 Receptor Agonists</h3> <h3>Other Emerging Therapies</h3> <h2>Risk of Bias and Quality Assessment of Included Evidence</h2> <h3>Assessment Methods</h3> <h3>Summary of Risk of Bias Findings</h3> <h2>Evaluation of Current Evidence and Research Limitations</h2> <h3>Strengths of the Evidence Base</h3> <h3>Weaknesses of Existing Studies</h3> <h3>Major Research Gaps</h3> <h2>Evaluation of Promising Pharmacological Strategies for Preventing Cirrhosis Decompensation</h2> <h3>Statins as Vascular Protective Agents</h3> <h3>Rifaximin and Gut–Liver Axis Modulation</h3> <h3>Anticoagulants for Portal Vein Thrombosis Prevention</h3> <h2>Clinical Implications and Future Research Priorities</h2> <h3>Implications for Clinical Practice</h3> <h3>Recommendations for Future Research</h3> <h2>Integrated Conclusions and Future Directions</h2> <h3>Overall Findings</h3> <h3>Evidence-Based Recommendations</h3> <h2>References</h2>